The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Omnicare, Inc. (“Omnicare” or the “Company”) (NYSE: OCR), concerning the Company’s proposed acquisition by CVS Health Corporation. Under the terms of the proposal, Omnicare shareholders will receive $98.00 in cash for each share of Omnicare common stock they own. At least one analyst has set a high target price of $104.00 for Omnicare shares. The entire transaction is valued at approximately $12.7 billion.

The investigation is focused on whether Omnicare’s Board of Directors breached its fiduciary duty in failing to maximize consideration to shareholders, the potential unfairness of the consideration to shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interest among Omnicare’s Board of Directors’ members.

If you are interested in discussing your rights as an Omnicare shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or (202) 337-8000, or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Finkelstein Thompson LLPRosalee B. C. Thomas, 877-337-1050rbcthomas@finkelsteinthompson.com

Omnicare (NYSE:OCR)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Omnicare Charts.
Omnicare (NYSE:OCR)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Omnicare Charts.